Clinical trials
Phase 3 Neurocognitive Disorders trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
5 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 2 |
| Alzheon Inc. | 1 |
| AstraZeneca | 1 |
| Hoffmann-La Roche | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alzheimer Disease | 5 |
| Central Nervous System Diseases | 5 |
| Dementia | 5 |
| Mental Disorders | 5 |
| Nervous System Diseases | 5 |
| Neurocognitive Disorders | 5 |
| Neurodegenerative Diseases | 5 |
| Brain Diseases | 4 |
| Tauopathies | 4 |
| Cognitive Dysfunction | 1 |
Trials
Showing 1 to 5 of 5. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.